Role for TNF in atherosclerosis? Lessons from autoimmune disease

被引:249
作者
McKellar, Gayle E. [2 ]
McCarey, David W. [2 ]
Sattar, Naveed [3 ]
McInnes, Iain B. [1 ]
机构
[1] Glasgow Biomed Res Ctr, Glasgow G12 8QQ, Lanark, Scotland
[2] Glasgow Royal Infirm, Ctr Rheumat Dis, Glasgow, Lanark, Scotland
[3] Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Glasgow G12 8QQ, Lanark, Scotland
关键词
TUMOR-NECROSIS-FACTOR; EVIDENT CARDIOVASCULAR-DISEASE; PSORIATIC-ARTHRITIS PATIENTS; CONGESTIVE-HEART-FAILURE; FACTOR-ALPHA THERAPY; RHEUMATOID-ARTHRITIS; ENDOTHELIAL DYSFUNCTION; MONOCLONAL-ANTIBODY; ARTERIAL STIFFNESS; LIPID PROFILE;
D O I
10.1038/nrcardio.2009.57
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Inflammatory pathways have been implicated in the initiation and progression of cardiovascular diseases. Accelerated atherosclerosis has been described in patients with chronic inflammatory diseases, particularly rheumatoid arthritis, disproportionate to individuals' detectable traditional vascular risk factors. This finding suggests that other pathways associated with inflammation might account for increased vascular risk in such diseases. Highly specific biologic agents can precisely block the activity of cytokines generated during inflammatory cascades; the effects of these inflammatory moieties on vascular physiology and overall risk of cardiovascular events has been directly evaluated. This review summarizes key epidemiologic, physiologic and model data, which together suggest that tumor necrosis factor, a pivotal cytokine in the inflammatory cascade, is directly involved in vascular pathophysiology and that its inhibition might confer an overall advantage to the recipient. Moreover, such data obtained in chronic inflammatory diseases likely have relevance to primary atherosclerosis.
引用
收藏
页码:410 / 417
页数:8
相关论文
共 75 条
[1]   Postsurgical reduction of serum lipoproteins: Interleukin-6 and the acute-phase response [J].
Akgun, S ;
Ertel, NH ;
Mosenthal, A ;
Oser, W .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1998, 131 (01) :103-108
[2]   CHANGES IN SERUM-LIPIDS AND LIPOPROTEINS IN CANCER-PATIENTS DURING CHEMOTHERAPY [J].
ALEXOPOULOS, CG ;
POURNARAS, S ;
VASLAMATZIS, M ;
AVGERINOS, A ;
RAPTIS, S .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1992, 30 (05) :412-416
[3]   Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis [J].
Allanore, Y ;
Kahan, A ;
Sellam, J ;
Ekindjian, OG ;
Borderie, D .
CLINICA CHIMICA ACTA, 2006, 365 (1-2) :143-148
[4]  
Avalos I, 2007, J RHEUMATOL, V34, P2388
[5]   Risk of Cardiovascular Mortality in Patients With Rheumatoid Arthritis: A Meta-Analysis of Observational Studies [J].
Avina-Zubieta, J. Antonio ;
Choi, Hyon K. ;
Sadatsafavi, Mohsen ;
Etminan, Mahyar ;
Esdaile, John M. ;
Lacaille, Diane .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2008, 59 (12) :1690-1697
[6]   A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [J].
Bathon, JM ;
Martin, RW ;
Fleischmann, RM ;
Tesser, JR ;
Schiff, MH ;
Keystone, EC ;
Genovese, MC ;
Wasko, MC ;
Moreland, LW ;
Weaver, AL ;
Markenson, J ;
Finck, BK .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1586-1593
[7]   Infliximab improves endothelial dysfunction in systemic vasculitis - A model of vascular inflammation [J].
Booth, AD ;
Jayne, DRW ;
Kharbanda, RK ;
McEniery, CM ;
Mackenzie, IS ;
Brown, J ;
Wilkinson, IB .
CIRCULATION, 2004, 109 (14) :1718-1723
[8]  
BRENNAN FM, 1989, LANCET, V2, P244
[9]  
Capell H, 2002, J RHEUMATOL, V29, P2099
[10]   The Th17/Treg imbalance in patients with acute coronary syndrome [J].
Cheng, Xiang ;
Yu, Xian ;
Ding, Ying-jun ;
Fu, Qing-qing ;
Xie, Jiang-jiao ;
Tang, Ting-ting ;
Yao, Rui ;
Chen, Yong ;
Liao, Yu-hua .
CLINICAL IMMUNOLOGY, 2008, 127 (01) :89-97